CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for YD Bio Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

YD Bio Ltd
12F, No. 3, Xingnan Street,
Nangang District
TAIPEI, 115  Taiwan Ticker: YDESYDES
Business Summary
YD Bio Ltd is a Taiwan-based company mainly focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization. The Company’s operations include deoxyribonucleic acid (DNA) methylation-based oncology testing programs in the United States. The Company also provides regulated life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology companies, including procurement, logistics coordination, and compliance-focused support for clinical development programs, as well as maintains ocular health product commercialization operations in the United States. The Company’s business model is centered on developing partnerships with biopharmaceutical companies to transform innovative technologies into commercially viable drugs and cancer detection.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer EthanShen 49 3/1/2024 3/1/2024
Chief Financial Officer EdmundHen 52 12/1/2024 12/1/2024
Director J. DouglasRamsey 65 8/1/2025 6/1/2020
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Breeze Acquisition Sub LLC 12920 SE 38th Street Bellevue WA United States

Business Names
Business Name
Breeze Acquisition Sub LLC
BRZH
YD Bio USA, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 13 (As of 12/31/2025)
Outstanding Shares: 70,831,346 (As of 4/29/2026)
Shareholders: 10
Stock Exchange: NASD
Federal Tax Id: 851849315


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, August 16, 2026